FDA Accepts Revance Resubmission for Frown Line Treatment
The FDA has accepted Revance's BLA resubmission for DaxibotulinumtoxinA for Injection, designed to treat severe glabellar lines.
The FDA has accepted Revance's BLA resubmission for DaxibotulinumtoxinA for Injection, designed to treat severe glabellar lines.
In the first installment of a two-part article series, YellowTelescope President Jon Hoffenberg shares how data can uncover hidden insights in staff retention.